Hydroxychloroquine as Pre-exposure Prophylaxis for Coronavirus Disease 2019 (COVID-19) in Healthcare Workers: A Randomized Trial
Radha Rajasingham(Fairview Health Services), Rebecca Zash, Mahsa Abassi(Fairview Health Services), Nicole Engen(Fairview Health Services), Lauren J MacKenzie(Fairview Health Services), Melanie R. Nicol(Fairview Health Services), Matthew F Pullen(Fairview Health Services), Brian I. Rini(CancerCare Manitoba), Glen Drobot(Fairview Health Services), David R. Boulware(Fairview Health Services), Lindsey Collins, Sylvain Lother(Fairview Health Services), Emily G. McDonald(McGill University Health Centre), Ryan Zarychanski, Dayna Solvason, Alanna A Nascene(Fairview Health Services), Cameron Meyer‐Mueller(University of Minnesota), Elizabeth C Okafor(Fairview Health Services), Todd C. Lee(McGill University Health Centre), Stephen Selinsky, Margaret L. Axelrod(Vanderbilt University Medical Center), Sarah M Lofgren(Fairview Health Services), Katherine Huppler Hullsiek(University of Minnesota), Ingrid A. Mayer(Vanderbilt University), Katelyn A Pastick(Fairview Health Services), Douglas Krakower, Dylan MacKay, Caleb P Skipper(Fairview Health Services), Justin M. Balko(Vanderbilt University Medical Center), Darlisha A Williams(University of Minnesota), Stephen J. Dunlop(University of Minnesota), Ananta Bangdiwala(University of Minnesota), Peter Li(Oregon Health & Science University), Andrew Balster
Cited by 128
Related Papers
A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19
|New England Journal of Medicine|2020|1.4k
Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206
|Journal of Clinical Oncology|2008|907
Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
|New England Journal of Medicine|2019|846
Estimating Survival in Patients With Lung Cancer and Brain Metastases
|JAMA Oncology|2016|655